Faes Farma SA (FAE)

3.300
-0.005(-0.15%)
  • Volume:
    374,795
  • Bid/Ask:
    3.290/3.320
  • Day's Range:
    3.260 - 3.315
High dividend Yield

Dividend yield shows how much a company pays its shareholders in dividends annually per dollar invested. It reflects how much an investor will earn aside from any capital gains in the stock.

FAE Overview

Prev. Close
3.3
Day's Range
3.26-3.315
Revenue
466.66M
Open
3.275
52 wk Range
3.035-4.29
EPS
0.296
Volume
374,795
Market Cap
1.01B
Dividend (Yield)
0.1763
(5.70%)
Average Volume (3m)
367,253
P/E Ratio
11.33
Beta
0.561
1-Year Change
-17.58%
Shares Outstanding
305,996,167
Next Earnings Date
03 Aug 2023
What is your sentiment on Faes Farma?
or
Market is currently closed. Voting is open during market hours.

Faes Farma SA Company Profile

Faes Farma SA Company Profile

Employees
1690
Market
Spain
  • Type:Equity
  • Market:Spain
  • ISIN:ES0134950F36

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and markets pharmaceutical products and raw materials in Spain and internationally. It operates through Pharmaceuticals and Healthcare Specialties, Animal Nutrition and Health, and Pharmaceutical Raw Materials segments. The company's products include prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn’s disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. In addition, it manufactures and sells animal nutrition and health products. Further, the company engages in distribution of medicine; and import of drugs, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing, and leasing corporations, securities and real estate, patents, trademarks, and registered brands and equity interests. It also exports its products. Faes Farma, S.A. was incorporated in 1933 and is headquartered in Leioa, Spain.

Read More

Analyst Price Target

Average3.845 (+16.515% Upside)
High4.330
Low3.500
Price3.300
No. of Analysts4
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Analysts Consensus

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuySellStrong SellSell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyNeutralStrong SellStrong Sell
  • dividend are 0.03Eur, not 0.22Eur
    0
    • https://www.actasanitaria.com/calcifediol-hospitalizados-covid-ingreso-uci/
      0
      • cuando baja, se despeña, y cuando sube, es un peo flojo, confirmado es una PM de valor
        0
        • valor defensivo su PM
          0
          • vendo y a TPC
            0
            • puta agonía de valor
              0